Cargando…

Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn

Antibodies with pH-dependent binding to both target antigens and neonatal Fc receptor (FcRn) provide an alternative tool to conventional neutralizing antibodies, particularly for therapies where reduction in antigen level is challenging due to high target burden. However, the requirements for optima...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Danlin, Giragossian, Craig, Castellano, Steven, Lasaro, Marcio, Xiao, Haiguang, Saraf, Himanshu, Hess Kenny, Cynthia, Rybina, Irina, Huang, Zhong-Fu, Ahlberg, Jennifer, Bigwarfe, Tammy, Myzithras, Maria, Waltz, Erica, Roberts, Simon, Kroe-Barrett, Rachel, Singh, Sanjaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627591/
https://www.ncbi.nlm.nih.gov/pubmed/28786732
http://dx.doi.org/10.1080/19420862.2017.1359455
_version_ 1783268743150829568
author Yang, Danlin
Giragossian, Craig
Castellano, Steven
Lasaro, Marcio
Xiao, Haiguang
Saraf, Himanshu
Hess Kenny, Cynthia
Rybina, Irina
Huang, Zhong-Fu
Ahlberg, Jennifer
Bigwarfe, Tammy
Myzithras, Maria
Waltz, Erica
Roberts, Simon
Kroe-Barrett, Rachel
Singh, Sanjaya
author_facet Yang, Danlin
Giragossian, Craig
Castellano, Steven
Lasaro, Marcio
Xiao, Haiguang
Saraf, Himanshu
Hess Kenny, Cynthia
Rybina, Irina
Huang, Zhong-Fu
Ahlberg, Jennifer
Bigwarfe, Tammy
Myzithras, Maria
Waltz, Erica
Roberts, Simon
Kroe-Barrett, Rachel
Singh, Sanjaya
author_sort Yang, Danlin
collection PubMed
description Antibodies with pH-dependent binding to both target antigens and neonatal Fc receptor (FcRn) provide an alternative tool to conventional neutralizing antibodies, particularly for therapies where reduction in antigen level is challenging due to high target burden. However, the requirements for optimal binding kinetic framework and extent of pH dependence for these antibodies to maximize target clearance from circulation are not well understood. We have identified a series of naturally-occurring high affinity antibodies with pH-dependent target binding properties. By in vivo studies in cynomolgus monkeys, we show that pH-dependent binding to the target alone is not sufficient for effective target removal from circulation, but requires Fc mutations that increase antibody binding to FcRn. Affinity-enhanced pH-dependent FcRn binding that is double-digit nM at pH 7.4 and single-digit nM at pH 6 achieved maximal target reduction when combined with similar target binding affinities in reverse pH directions. Sustained target clearance below the baseline level was achieved 3 weeks after single-dose administration at 1.5 mg/kg. Using the experimentally derived mechanistic model, we demonstrate the essential kinetic interplay between target turnover and antibody pH-dependent binding during the FcRn recycling, and identify the key components for achieving maximal target clearance. These results bridge the demand for improved patient dosing convenience with the “know-how” of therapeutic modality by design.
format Online
Article
Text
id pubmed-5627591
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-56275912017-10-12 Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn Yang, Danlin Giragossian, Craig Castellano, Steven Lasaro, Marcio Xiao, Haiguang Saraf, Himanshu Hess Kenny, Cynthia Rybina, Irina Huang, Zhong-Fu Ahlberg, Jennifer Bigwarfe, Tammy Myzithras, Maria Waltz, Erica Roberts, Simon Kroe-Barrett, Rachel Singh, Sanjaya MAbs Report Antibodies with pH-dependent binding to both target antigens and neonatal Fc receptor (FcRn) provide an alternative tool to conventional neutralizing antibodies, particularly for therapies where reduction in antigen level is challenging due to high target burden. However, the requirements for optimal binding kinetic framework and extent of pH dependence for these antibodies to maximize target clearance from circulation are not well understood. We have identified a series of naturally-occurring high affinity antibodies with pH-dependent target binding properties. By in vivo studies in cynomolgus monkeys, we show that pH-dependent binding to the target alone is not sufficient for effective target removal from circulation, but requires Fc mutations that increase antibody binding to FcRn. Affinity-enhanced pH-dependent FcRn binding that is double-digit nM at pH 7.4 and single-digit nM at pH 6 achieved maximal target reduction when combined with similar target binding affinities in reverse pH directions. Sustained target clearance below the baseline level was achieved 3 weeks after single-dose administration at 1.5 mg/kg. Using the experimentally derived mechanistic model, we demonstrate the essential kinetic interplay between target turnover and antibody pH-dependent binding during the FcRn recycling, and identify the key components for achieving maximal target clearance. These results bridge the demand for improved patient dosing convenience with the “know-how” of therapeutic modality by design. Taylor & Francis 2017-08-08 /pmc/articles/PMC5627591/ /pubmed/28786732 http://dx.doi.org/10.1080/19420862.2017.1359455 Text en © 2017 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Report
Yang, Danlin
Giragossian, Craig
Castellano, Steven
Lasaro, Marcio
Xiao, Haiguang
Saraf, Himanshu
Hess Kenny, Cynthia
Rybina, Irina
Huang, Zhong-Fu
Ahlberg, Jennifer
Bigwarfe, Tammy
Myzithras, Maria
Waltz, Erica
Roberts, Simon
Kroe-Barrett, Rachel
Singh, Sanjaya
Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn
title Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn
title_full Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn
title_fullStr Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn
title_full_unstemmed Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn
title_short Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn
title_sort maximizing in vivo target clearance by design of ph-dependent target binding antibodies with altered affinity to fcrn
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627591/
https://www.ncbi.nlm.nih.gov/pubmed/28786732
http://dx.doi.org/10.1080/19420862.2017.1359455
work_keys_str_mv AT yangdanlin maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT giragossiancraig maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT castellanosteven maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT lasaromarcio maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT xiaohaiguang maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT sarafhimanshu maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT hesskennycynthia maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT rybinairina maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT huangzhongfu maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT ahlbergjennifer maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT bigwarfetammy maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT myzithrasmaria maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT waltzerica maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT robertssimon maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT kroebarrettrachel maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn
AT singhsanjaya maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn